Bundibugyo Ebolavirus Virus-Like Particles - VP40/GP/NP VLP

Availability: Expected to ship in August 2026.

Description: This virus-like particle is comprised of the Bundibugyo ebolavirus VP40 Matrix protein, the ebolavirus GP Glycoprotein and the ebolavirus NP Nucleoprotein. This VLP is non-infectious and non-replicating as it lacks viral genetic material.

Strain History: Bundibugyo ebolavirus emerged as a distinct species of ebolavirus during a 2007 outbreak in western Uganda. The genomic sequence in available in NCBI.

Passage History: Vero E6 (2). References (1) and (2).

Production: Co-transfection of VP40, GP and NP expressing plasmids into human embryonic kidney 293T (HEK 293T) cells. Collected supernatant purified and concentrated by sucrose gradient centrifugation.

Biosafety Level: 2

Formulation: 1.0 mg of protein suspended in PBS.

Format: 1.0 mL/vial. Purified and concentrated cell culture supernatant frozen at -80°C. Delivered on dry ice.

QA/QC:

• Protein concentration
• Mycoplasma test by PCR
• Sterility test for bacterial and fungal contamination
• Endotoxin test <0.25 EU/mL
• Electron microscopy imaging to confirm VLP structure
• Documentation: Experimental conditions for QC tests

Production Batch Information links (downloadable):

Certificate of Analysis

Batch Record: Detailed Production and QC Data

Product Use Policy and Material Transfer Agreement

Additional Strains: If you require a VLP for a different ebolavirus strain, please contact us. We can produce VLPs from multiple ebolavirus strains to meet your needs.

Additional Viruses Available: If you are looking for a virus species or strain not listed on our website, please contact us with your request. Our team of experts will work with you to create the product that meets your research needs and budget.